SCHEMBL9749511

SCHEMBL9749511

O=[N+]([O-])c1cc(NS(=O)(=O)c2ccccc2)ccc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.71
HSPD1 P10809 2/20 0.59
PTPN2 P17706 2/20 0.59
PTPN1 P18031 2/20 0.59
PTPN5 P54829 2/20 0.59
HSPE1 P61604 2/20 0.59
DNMT1 P26358 1/20 0.58
DNMT3A Q9Y6K1 1/20 0.58
SLC25A1 P53007 1/20 0.58
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
MAPT P10636 3/20 0.57
LMNA P02545 3/20 0.57
GAA P10253 1/20 0.57
HTT P42858 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
VCAM1 P19320 5/20 0.56
CRHBP P24387 2/20 0.56
CRHR2 Q13324 2/20 0.56
ALDH1A1 P00352 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27809726 0.87 VCAM1 (0.61) FFAR4HSPD1PTPN2PTPN1PTPN5
SCHEMBL3619380 0.87 SLC25A1 (0.67) FFAR4HSPD1PTPN2PTPN1PTPN5
SCHEMBL7371667 0.85 KMT2A (0.62) FFAR4DNMT1DNMT3ASLC25A1KMT2A
SCHEMBL5225915 0.84 VCAM1 (0.64) FFAR4HSPD1PTPN2PTPN1PTPN5
SCHEMBL6570574 0.83 ALDH1A1 (0.72) FFAR4KMT2AMEN1MAPTLMNA
SCHEMBL8026293 0.83 FFAR4 (0.71) FFAR4DNMT1DNMT3AKMT2AMEN1
SCHEMBL4968417 0.83 FFAR4 (0.71) FFAR4KMT2AMEN1MAPTLMNA
SCHEMBL17557158 0.83 FFAR4 (0.71) FFAR4KMT2AMEN1MAPTLMNA
SCHEMBL10618991 0.83 FFAR4 (1.00) FFAR4KMT2AMEN1MAPTLMNA
SCHEMBL5059972 0.83 KMT2A (0.57) FFAR4HSPD1PTPN2PTPN1PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1329382-C Novel arylsusfonamide compounds for treatment of obesity, type II diabetes and CNS-disorders BIOVITRUM AB (SE) 2007-08-01 CN disclosed
CN-1531531-A Novel arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders �Ȱ�ά����ķ�ɷݹ�˾ 2004-09-22 CN disclosed
US-5132461-A Process for the production of 4-[ethyl-(2'-hydroxyethyl)-amino]-1-[(2'-hydroxyethyl)-amino]-2-nitro-benzene WELLA AKTIENGESELLSCHAFT (DE) 1992-07-21 US disclosed
US-4900869-A Process for the production of 4-[ethyl-(2'-hydroxyethyl)-amino]-1-[(2'-hydroxyethyl)-amino]-2-nitrobenzene Wella, Aktiengesellschaft (DE) 1990-02-13 US disclosed
US-3978061-A HAIR DYES L'OREAL (FR) 1976-08-31 US disclosed